Kairos Pharma, Ltd.
KAPA
$1.20
-$0.03-2.44%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 503.77% | 533.61% | 17.74% | 45.28% | -9.66% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 555.86% | 341.11% | 32.78% | 33.45% | 4.72% |
| Operating Income | -555.86% | -341.11% | -32.78% | -33.45% | -4.72% |
| Income Before Tax | -462.06% | -290.71% | 12.34% | -235.58% | -7.20% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -462.06% | -290.71% | 12.34% | -235.58% | -7.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -462.06% | -290.71% | 12.34% | -235.58% | -7.20% |
| EBIT | -555.86% | -341.11% | -32.78% | -33.45% | -4.72% |
| EBITDA | -678.02% | -396.36% | -34.03% | -38.87% | -5.81% |
| EPS Basic | -244.17% | -159.80% | 31.07% | -217.88% | -5.26% |
| Normalized Basic EPS | -244.00% | -160.21% | -10.99% | -217.46% | -4.90% |
| EPS Diluted | -244.17% | -159.80% | 31.07% | -217.88% | -5.26% |
| Normalized Diluted EPS | -244.00% | -160.21% | -10.99% | -217.46% | -4.90% |
| Average Basic Shares Outstanding | 62.96% | 50.30% | 27.16% | 5.57% | 2.21% |
| Average Diluted Shares Outstanding | 62.96% | 50.30% | 27.16% | 5.57% | 2.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |